 |
17 Diseases |  |
0 Trials |
|
0 Trials |  |
2 News |  |
- ||| Peglamda (peginterferon lamda 1) / Nanogen Biopharma
Trial completion, Phase classification, Trial primary completion date: The Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients (clinicaltrials.gov) - Dec 15, 2016
P1a/1b, N=60, Completed, Sponsor: Nanogen Pharmaceutical Biotechnology Co., Ltd
Recruiting --> Completed | Phase classification: P1 --> P1a/1b | Trial primary completion date: Jul 2014 --> Feb 2015
- ||| Peglamda (peginterferon lamda 1) / Nanogen Biopharma
New P1 trial: The Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients (clinicaltrials.gov) - Feb 12, 2014
P1, N=60, Recruiting, Sponsor: Nanogen Pharmaceutical Biotechnology Co., Ltd